Merseyside Inter Agency Drug Misuse Database

Sefton DAAT

**Lloyd Baron, Martin Chandler,
Jim McVeigh**

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Table 1: Individuals assessed, by Gender
and Age Group
Table 2: Year to Date, by Gender and Age Group
Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Table 4: Individuals by Gender
Table 5: Individuals by Gender: Steroid Users omitted
Table 6: Individuals by Age Group
Table 7: Individuals by Age Group: Steroid Users omitted
Table 8: Gender by Age Group of Individuals
Table 9: Gender by Age Group: Steroid Users omitted
Table 10: Year to Date, by Gender & Age Group
Table 11: Year to Date, by Gender & Age Group: Steroid Users
omitted
Table 12: Main Drug of Use for New Agency Syringe Exchange
Clients, by Gender
Table 13: Main Drug of Use, for New Agency Syringe Exchange
Clients, by Age Group

Table 14: Individuals by Gender
Table 15: Individuals by Age Group
Table 16: Year to Date, by Gender & Age Group

Table 17: Individuals in Syringe Exchange, by Gender
Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users
omitted
Table 19: Individuals in Syringe Exchange, by Age Group
Table 20: Individuals in Syringe Exchange, by Age Group: Steroid
Users omitted
Table 21: Year to Date, by Gender & Age Group
Table 22: Total Syringes Provided

National Drug Treatment Monitoring System (NDTMS)   13

Connexions   16

Combined Datasets   18

Cross Matched Datasets   19

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2007/08)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	119	78.8
Female	32	21.2
Age Group		
Under 18	0	0.0
18-19	8	5.3
20-24	29	19.2
25-29	27	17.9
30-34	18	11.9
35-39	24	15.9
40-44	24	15.9
45+	21	13.9
Total	*151*	*100*

Table 2: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	28	7.3	5	4.2	33	6.6
20-24	77	20.2	17	14.3	94	18.8
25-29	58	15.2	19	16.0	77	15.4
30-34	61	16.0	31	26.1	92	18.4
35-39	69	18.1	23	19.3	92	18.4
40-44	51	13.4	20	16.8	71	14.2
45+	38	9.9	4	3.4	42	8.4
Total	*382*	*100*	*119*	*100*	*501*	*100*

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	2	1
Cannabis	20	2
Crack	46	18
Cocaine	9	22
Ecstasy	0	0
Heroin	63	7
Methadone	8	1
Other	0	1

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES
Quarter 4 (2007/08)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	32	94.1
Female	2	5.9
Total	34	100
All Clients		
Male	154	90.6
Female	16	9.4
Total	170	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	14	87.5
Female	2	12.5
Total	16	100
All Clients		
Male	104	87.4
Female	15	12.6
Total	119	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	2	1.2
20-24	9	26.5	18	10.6
25-29	8	23.5	21	12.4
30-34	6	17.6	31	18.2
35-39	2	5.9	48	28.2
40-44	6	17.6	34	20.0
45+	3	8.8	16	9.4
Total	*34*	*100*	*170*	*100*

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	1	>1
20-24	0	0.0	6	5.0
25-29	4	25.0	10	8.4
30-34	4	25.0	14	11.8
35-39	2	12.5	46	38.7
40-44	4	25.0	28	23.5
45+	2	12.5	14	11.8
Total	*16*	*100*	*119*	*100*

Table 8: Gender by Age Group of Individuals

| Age Group | Gender | | | |
| | Male | | Female | |
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	1.3	0	0.0
20-24	18	11.7	0	0.0
25-29	18	11.7	3	18.8
30-34	28	18.2	3	18.8
35-39	42	27.3	6	37.5
40-44	32	20.8	2	12.5
45+	14	9.1	2	12.5
Total	154	100	16	100

Table 9: Gender by Age Group: Steroid Users omitted

| Age Group | Gender | | | |
| | Male | | Female | |
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	1.0	0	0.0
20-24	6	5.8	0	0.0
25-29	7	6.7	3	20.0
30-34	12	11.5	2	13.3
35-39	40	38.5	6	40.0
40-44	26	25.0	2	13.3
45+	12	11.5	2	13.3
Total	104	100	15	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Male		Female		Total in Age Group	
	n	**%**	**n**	**%**	**n**	**%**
Under 18	1	>1	0	0.0	1	<1
18-19	8	1.6	0	0.0	8	1.4
20-24	58	11.6	2	2.7	60	10.5
25-29	80	16.0	9	12.2	89	15.5
30-34	72	14.4	19	25.7	91	15.9
35-39	144	28.9	22	29.7	166	29.0
40-44	85	17.0	15	20.3	100	17.5
45+	51	10.2	7	9.5	58	10.1
Total	499	100	74	100	573	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Male		Female		Total in Age Group	
	n	**%**	**n**	**%**	**n**	**%**
Under 18	1	<1	0	0.0	1	<1
18-19	2	<1	0	0.0	2	<1
20-24	19	5.8	2	2.8	21	5.3
25-29	35	10.7	8	11.3	43	10.8
30-34	37	11.3	17	23.9	54	13.6
35-39	124	38.0	22	31.0	146	36.8
40-44	70	21.5	15	21.1	85	21.4
45+	38	11.7	7	9.9	45	11.3
Total	326	100	71	100	397	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	9	28.1	1	50.0
Methadone	1	3.1	1	50.0
Steroids	18	56.3	0	0.0
Other	4	12.5	0	0.0
Total	*32*	*100*	*2*	*100*

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
Age Group	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20-24	-	-	-	-	-	-	-	-	-	-	-	-	9	50.0
25-29	-	-	-	-	-	-	-	-	1	10.0	1	50.0	4	22.0
30-34	-	-	-	-	-	-	-	-	3	30.0	-	-	2	11.0
35-39	-	-	-	-	-	-	-	-	1	10.0	-	-	-	-
40-44	-	-	-	-	-	-	-	-	3	30.0	1	50.0	2	11.0
45+	-	-	-	-	-	-	-	-	2	20.0	-	-	1	6.0
Total	-	-	-	-	-	-	-	-	*10*	*100*	*2*	*100*	*18*	*100*

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	302	84.1
Female	57	15.9
Total	359	100
All Clients		
Male	520	83.2
Female	105	16.8
Total	625	100

Table 15: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	>1	3	>1
20-24	21	5.8	34	5.4
25-29	49	13.6	72	11.5
30-34	58	16.2	98	15.7
35-39	114	31.8	200	32.0
40-44	52	14.5	113	18.1
45+	63	17.5	105	16.8
Total	359	100	625	100

Table 16: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	2	>1	0	0.0	2	>1
18-19	7	>1	1	>1	8	>1
20-24	68	7.0	4	2.1	72	6.2
25-29	114	11.7	42	22.0	156	13.4
30-34	151	15.5	43	22.5	194	16.7
35-39	286	29.4	56	29.3	342	29.4
40-44	183	18.8	30	15.7	213	18.3
45+	162	16.6	15	7.9	177	15.2
Total	973	100	191	100	1164	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	330	84.8
Female	59	15.2
Total	389	100
All Clients		
Male	656	84.5
Female	120	15.5
Total	776	100

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	310	84.0
Female	59	16.0
Total	369	100
All Clients		
Male	603	83.5
Female	119	16.5
Total	722	100

Table 19: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	>1	5	>1
20-24	30	7.7	51	6.6
25-29	57	14.7	92	11.9
30-34	64	16.5	128	16.5
35-39	113	29.0	236	30.4
40-44	57	14.7	144	18.6
45+	66	17.0	120	15.5
Total	389	100	776	100

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	>1	4	>1
20-24	20	5.4	38	5.3
25-29	53	14.4	81	11.2
30-34	61	16.5	110	15.2
35-39	113	30.6	234	32.4
40-44	55	14.9	138	19.1
45+	65	17.6	117	16.2
Total	369	100	722	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	>1	0	0.0	3	>1
18-19	15	1.1	1	>1	16	1.0
20-24	125	9.0	5	2.1	130	8.0
25-29	187	13.4	47	19.3	234	14.3
30-34	214	15.4	55	22.6	269	16.5
35-39	394	28.3	75	30.9	469	28.7
40-44	251	18.0	39	16.0	290	17.7
45+	202	14.5	21	8.6	223	13.6
Total	1391	100	243	100	1634	100

Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	5,575	35,390	40,965	163,903

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2007/08)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	185	71.43
Female	74	28.57
Total	259	100
All Clients		
Male	1250	70.8
Female	514	29.2
Total	1764	100

Table 24: Year to Date, by Gender

New Clients	n	%
Male	632	71.6
Female	251	28.4
Total	883	100
All Clients		
Male	1389	70.7
Female	576	29.3
Total	1965	100

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	24	9.2	112	6.3
18-19	4	1.5	43	2.4
20-24	17	6.5	101	5.7
25-29	30	11.5	175	9.9
30-34	43	16.6	277	15.7
35-39	75	28.9	488	27.6
40-44	33	12.7	341	19.3
45+	33	12.7	227	12.8
Total	259	100	1764	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	103	11.7	136	6.9
18-19	17	1.9	33	1.7
20-24	66	7.5	173	8.8
25-29	116	13.1	267	13.6
30-34	168	19.0	420	21.4
35-39	208	23.6	495	25.2
40-44	117	13.3	269	13.7
45+	88	10.0	172	8.8
Total	883	100	1965	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	249	96.1	1722	97.6
White Irish	1	>1	5	>1
Other White	2	>1	11	>1
White & Black Caribbean	1	>1	1	>1
White & Black African	0	0.0	1	>1
Other Mixed	0	0.0	3	>1
Other Asian	0	0.0	2	>1
African	2	>1	3	>1
Other Black	1	>1	4	>1
Other	1	>1	7	>1
Unknown	2	>1	5	>1
Total	*259*	*100*	*1764*	*100*

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	141	54.4	1102	62.4
Methadone	21	8.1	105	5.9
Other Opiates	5	1.9	15	>1
Benzodiazepine	0	0.0	9	>1
Amphetamines	1	>1	15	>1
Cocaine	32	12.3	229	12.9
Crack	6	2.3	42	2.3
Ecstasy	1	>1	11	>1
Cannabis	45	17.3	202	11.4
Solvents	1	>1	4	>1
Anti-depressants	0	0.0	2	>1
Other/Unknown	6	2.3	28	2.0
Total	*259*	*100*	*1764*	*100*

CONNEXIONS
Quarter 4 (2007/08)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	42	60.9
Female	27	39.1
Total	69	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	70	61.9
Female	43	38.1
Total	113	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	24	34.8
17	21	30.4
18	13	18.8
19	11	15.9
Total	69	100

Table 32: Year to Date, by Age

Age Group	n	%
16	35	31.0
17	30	26.5
18	24	21.2
19	24	21.2
Total	113	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	15	21.7
Drugs	54	78.3
Total	*69*	*100*

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	33	29.2
Drugs	80	70.8
Total	*113*	*100*

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS
Quarter 4 (2007/08)

Introduction
Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1871	74.8
Female	631	25.2
Age Group		
Under 18	168	6.7
18-19	65	2.6
20-24	231	9.2
25-29	321	12.8
30-34	461	18.4
35-39	624	24.9
40-44	356	14.2
45+	276	11.0
Total	*2502*	*100*

Table 36: Year to Date, by Gender and Age Group

	Gender					
	Male		**Female**		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	*n*	*%*
Under 18	128	4.4	46	5.5	*174*	*4.6*
18-19	107	3.7	32	3.8	*139*	*3.7*
20-24	295	10.1	46	5.5	*341*	*9.1*
25-29	351	12.0	116	13.8	*467*	*12.4*
30-34	448	15.4	159	18.9	*607*	*16.2*
35-39	710	24.4	225	26.7	*935*	*24.9*
40-44	493	16.9	139	16.5	*632*	*16.8*
45+	381	13.1	80	9.5	*461*	*12.3*
Total	*2913*	*100*	*843*	*100*	*3756*	*100*

CROSS-MATCHED DATASETS
Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY
(119)

69 Male
9 Female

NDTMS
(1764)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY
(625)

130 Male
34 Female

NDTMS
(1764)